Health Is A Political Choice – But Should Health Officials Be Politicians Or Professionals? 19/11/2019 Armando Bartolazzi Italy’s former Undersecretary of State for Health, Armando Bartolazzi, discusses the implications of recent moves to replace the head of the Italian Medicines Agency (AIFA), based on political considerations of the a new Health Minister. “Health is a Political Choice” said WHO Director-General Dr Tedros in his keynote session at the World Health Summit, […] Continue reading -> WHO & African Union Sign MOU To Expand Access To Medicines & Bolster Epidemic Preparedness 18/11/2019 Grace Ren The World Health Organization and African Union have signed a sweeping Memorandum of Understanding to collaborate on improving access to medicines, strengthening epidemic preparedness, and expanding universal health coverage across the African continent. These are the three main pillars of the MOU signed Monday by the WHO Director-General Dr Tedros Adhanom Ghebreyesus and African Union Chair […] Continue reading -> Time For A New Deal For Medicine; EPHA Forum Challenges Status Quo On Medicines Policy 14/11/2019 Grace Ren The debate around drug price transparency was a highlight of the 4th Forum on Access to Medicines in Europe, hosted by the European Public Health Alliance (EPHA) Thursday. The forum focused its discussions around cancer therapies, medicines shortages, and transparency around R&D costs. “It is high time to challenge the status quo on medicines policy […] Continue reading -> First-Ever Ebola Vaccine Gets World Health Organization “Pre-Qual” Seal of Approval 12/11/2019 Elaine Ruth Fletcher The World Health Organization has “pre-qualified” a new Ebola vaccine in record time, just a day after the vaccine, Ervebo, received European regulatory approval. “This is the fastest vaccine prequalification process ever conducted by WHO,” said the organization in press release Tuesday evening. The WHO approval was described as a “critical step that will help […] Continue reading -> Medicines for Malaria Venture At 20 Years: A Perfect Moment For New Innovation 11/11/2019 Elaine Ruth Fletcher MMV CEO David Reddy talks about the steps MMV is taking to support a new generation of malaria research leadership, promote more gender-sensitive malaria treatment and fast-track innovation on new malaria combination therapies. This follows a string of MMV successes over the past two decades in fostering new paediatric malaria treatments, new combination therapies to […] Continue reading -> Italian Health Minister Moves To Replace Key Architect of WHA Resolution On Drug Price Transparency 07/11/2019 Elaine Ruth Fletcher In a move fraught with international political overtones, Italy’s new Minister of Health is moving to replace the Director General of the Italian Drug Agency (AIFA), Dr Luca Li Bassi, who was the key architect of the May World Health Assembly (WHA) resolution supporting greater price transparency in medicines markets, Health Policy Watch has learned. […] Continue reading -> Civil Society Pressures French Leaders To Adopt Transparency Amendments 06/11/2019 Grace Ren A coalition of over 40 personalities – from doctors and economists to actors and health access activists – released an open letter Tuesday calling on the French Prime Minister Edouard Philippe and the Minister of Health Agnès Buzyn to support a series of amendments to the French Social Security Budget Bill for 2020 providing for […] Continue reading -> Challenges & Opportunities Of Cutting-Edge Health Technologies Discussed At WTO-WHO-WIPO Symposium 31/10/2019 Grace Ren Cutting-edge health technologies – such as gene editing therapies for cancer – have the potential to save lives, and the international intellectual property system should be leveraged to drive innovation and bring those therapies to people who need them, said the leaders of global health, trade and intellectual property agencies at a Trilateral Symposium on […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO & African Union Sign MOU To Expand Access To Medicines & Bolster Epidemic Preparedness 18/11/2019 Grace Ren The World Health Organization and African Union have signed a sweeping Memorandum of Understanding to collaborate on improving access to medicines, strengthening epidemic preparedness, and expanding universal health coverage across the African continent. These are the three main pillars of the MOU signed Monday by the WHO Director-General Dr Tedros Adhanom Ghebreyesus and African Union Chair […] Continue reading -> Time For A New Deal For Medicine; EPHA Forum Challenges Status Quo On Medicines Policy 14/11/2019 Grace Ren The debate around drug price transparency was a highlight of the 4th Forum on Access to Medicines in Europe, hosted by the European Public Health Alliance (EPHA) Thursday. The forum focused its discussions around cancer therapies, medicines shortages, and transparency around R&D costs. “It is high time to challenge the status quo on medicines policy […] Continue reading -> First-Ever Ebola Vaccine Gets World Health Organization “Pre-Qual” Seal of Approval 12/11/2019 Elaine Ruth Fletcher The World Health Organization has “pre-qualified” a new Ebola vaccine in record time, just a day after the vaccine, Ervebo, received European regulatory approval. “This is the fastest vaccine prequalification process ever conducted by WHO,” said the organization in press release Tuesday evening. The WHO approval was described as a “critical step that will help […] Continue reading -> Medicines for Malaria Venture At 20 Years: A Perfect Moment For New Innovation 11/11/2019 Elaine Ruth Fletcher MMV CEO David Reddy talks about the steps MMV is taking to support a new generation of malaria research leadership, promote more gender-sensitive malaria treatment and fast-track innovation on new malaria combination therapies. This follows a string of MMV successes over the past two decades in fostering new paediatric malaria treatments, new combination therapies to […] Continue reading -> Italian Health Minister Moves To Replace Key Architect of WHA Resolution On Drug Price Transparency 07/11/2019 Elaine Ruth Fletcher In a move fraught with international political overtones, Italy’s new Minister of Health is moving to replace the Director General of the Italian Drug Agency (AIFA), Dr Luca Li Bassi, who was the key architect of the May World Health Assembly (WHA) resolution supporting greater price transparency in medicines markets, Health Policy Watch has learned. […] Continue reading -> Civil Society Pressures French Leaders To Adopt Transparency Amendments 06/11/2019 Grace Ren A coalition of over 40 personalities – from doctors and economists to actors and health access activists – released an open letter Tuesday calling on the French Prime Minister Edouard Philippe and the Minister of Health Agnès Buzyn to support a series of amendments to the French Social Security Budget Bill for 2020 providing for […] Continue reading -> Challenges & Opportunities Of Cutting-Edge Health Technologies Discussed At WTO-WHO-WIPO Symposium 31/10/2019 Grace Ren Cutting-edge health technologies – such as gene editing therapies for cancer – have the potential to save lives, and the international intellectual property system should be leveraged to drive innovation and bring those therapies to people who need them, said the leaders of global health, trade and intellectual property agencies at a Trilateral Symposium on […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Time For A New Deal For Medicine; EPHA Forum Challenges Status Quo On Medicines Policy 14/11/2019 Grace Ren The debate around drug price transparency was a highlight of the 4th Forum on Access to Medicines in Europe, hosted by the European Public Health Alliance (EPHA) Thursday. The forum focused its discussions around cancer therapies, medicines shortages, and transparency around R&D costs. “It is high time to challenge the status quo on medicines policy […] Continue reading -> First-Ever Ebola Vaccine Gets World Health Organization “Pre-Qual” Seal of Approval 12/11/2019 Elaine Ruth Fletcher The World Health Organization has “pre-qualified” a new Ebola vaccine in record time, just a day after the vaccine, Ervebo, received European regulatory approval. “This is the fastest vaccine prequalification process ever conducted by WHO,” said the organization in press release Tuesday evening. The WHO approval was described as a “critical step that will help […] Continue reading -> Medicines for Malaria Venture At 20 Years: A Perfect Moment For New Innovation 11/11/2019 Elaine Ruth Fletcher MMV CEO David Reddy talks about the steps MMV is taking to support a new generation of malaria research leadership, promote more gender-sensitive malaria treatment and fast-track innovation on new malaria combination therapies. This follows a string of MMV successes over the past two decades in fostering new paediatric malaria treatments, new combination therapies to […] Continue reading -> Italian Health Minister Moves To Replace Key Architect of WHA Resolution On Drug Price Transparency 07/11/2019 Elaine Ruth Fletcher In a move fraught with international political overtones, Italy’s new Minister of Health is moving to replace the Director General of the Italian Drug Agency (AIFA), Dr Luca Li Bassi, who was the key architect of the May World Health Assembly (WHA) resolution supporting greater price transparency in medicines markets, Health Policy Watch has learned. […] Continue reading -> Civil Society Pressures French Leaders To Adopt Transparency Amendments 06/11/2019 Grace Ren A coalition of over 40 personalities – from doctors and economists to actors and health access activists – released an open letter Tuesday calling on the French Prime Minister Edouard Philippe and the Minister of Health Agnès Buzyn to support a series of amendments to the French Social Security Budget Bill for 2020 providing for […] Continue reading -> Challenges & Opportunities Of Cutting-Edge Health Technologies Discussed At WTO-WHO-WIPO Symposium 31/10/2019 Grace Ren Cutting-edge health technologies – such as gene editing therapies for cancer – have the potential to save lives, and the international intellectual property system should be leveraged to drive innovation and bring those therapies to people who need them, said the leaders of global health, trade and intellectual property agencies at a Trilateral Symposium on […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
First-Ever Ebola Vaccine Gets World Health Organization “Pre-Qual” Seal of Approval 12/11/2019 Elaine Ruth Fletcher The World Health Organization has “pre-qualified” a new Ebola vaccine in record time, just a day after the vaccine, Ervebo, received European regulatory approval. “This is the fastest vaccine prequalification process ever conducted by WHO,” said the organization in press release Tuesday evening. The WHO approval was described as a “critical step that will help […] Continue reading -> Medicines for Malaria Venture At 20 Years: A Perfect Moment For New Innovation 11/11/2019 Elaine Ruth Fletcher MMV CEO David Reddy talks about the steps MMV is taking to support a new generation of malaria research leadership, promote more gender-sensitive malaria treatment and fast-track innovation on new malaria combination therapies. This follows a string of MMV successes over the past two decades in fostering new paediatric malaria treatments, new combination therapies to […] Continue reading -> Italian Health Minister Moves To Replace Key Architect of WHA Resolution On Drug Price Transparency 07/11/2019 Elaine Ruth Fletcher In a move fraught with international political overtones, Italy’s new Minister of Health is moving to replace the Director General of the Italian Drug Agency (AIFA), Dr Luca Li Bassi, who was the key architect of the May World Health Assembly (WHA) resolution supporting greater price transparency in medicines markets, Health Policy Watch has learned. […] Continue reading -> Civil Society Pressures French Leaders To Adopt Transparency Amendments 06/11/2019 Grace Ren A coalition of over 40 personalities – from doctors and economists to actors and health access activists – released an open letter Tuesday calling on the French Prime Minister Edouard Philippe and the Minister of Health Agnès Buzyn to support a series of amendments to the French Social Security Budget Bill for 2020 providing for […] Continue reading -> Challenges & Opportunities Of Cutting-Edge Health Technologies Discussed At WTO-WHO-WIPO Symposium 31/10/2019 Grace Ren Cutting-edge health technologies – such as gene editing therapies for cancer – have the potential to save lives, and the international intellectual property system should be leveraged to drive innovation and bring those therapies to people who need them, said the leaders of global health, trade and intellectual property agencies at a Trilateral Symposium on […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Medicines for Malaria Venture At 20 Years: A Perfect Moment For New Innovation 11/11/2019 Elaine Ruth Fletcher MMV CEO David Reddy talks about the steps MMV is taking to support a new generation of malaria research leadership, promote more gender-sensitive malaria treatment and fast-track innovation on new malaria combination therapies. This follows a string of MMV successes over the past two decades in fostering new paediatric malaria treatments, new combination therapies to […] Continue reading -> Italian Health Minister Moves To Replace Key Architect of WHA Resolution On Drug Price Transparency 07/11/2019 Elaine Ruth Fletcher In a move fraught with international political overtones, Italy’s new Minister of Health is moving to replace the Director General of the Italian Drug Agency (AIFA), Dr Luca Li Bassi, who was the key architect of the May World Health Assembly (WHA) resolution supporting greater price transparency in medicines markets, Health Policy Watch has learned. […] Continue reading -> Civil Society Pressures French Leaders To Adopt Transparency Amendments 06/11/2019 Grace Ren A coalition of over 40 personalities – from doctors and economists to actors and health access activists – released an open letter Tuesday calling on the French Prime Minister Edouard Philippe and the Minister of Health Agnès Buzyn to support a series of amendments to the French Social Security Budget Bill for 2020 providing for […] Continue reading -> Challenges & Opportunities Of Cutting-Edge Health Technologies Discussed At WTO-WHO-WIPO Symposium 31/10/2019 Grace Ren Cutting-edge health technologies – such as gene editing therapies for cancer – have the potential to save lives, and the international intellectual property system should be leveraged to drive innovation and bring those therapies to people who need them, said the leaders of global health, trade and intellectual property agencies at a Trilateral Symposium on […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Italian Health Minister Moves To Replace Key Architect of WHA Resolution On Drug Price Transparency 07/11/2019 Elaine Ruth Fletcher In a move fraught with international political overtones, Italy’s new Minister of Health is moving to replace the Director General of the Italian Drug Agency (AIFA), Dr Luca Li Bassi, who was the key architect of the May World Health Assembly (WHA) resolution supporting greater price transparency in medicines markets, Health Policy Watch has learned. […] Continue reading -> Civil Society Pressures French Leaders To Adopt Transparency Amendments 06/11/2019 Grace Ren A coalition of over 40 personalities – from doctors and economists to actors and health access activists – released an open letter Tuesday calling on the French Prime Minister Edouard Philippe and the Minister of Health Agnès Buzyn to support a series of amendments to the French Social Security Budget Bill for 2020 providing for […] Continue reading -> Challenges & Opportunities Of Cutting-Edge Health Technologies Discussed At WTO-WHO-WIPO Symposium 31/10/2019 Grace Ren Cutting-edge health technologies – such as gene editing therapies for cancer – have the potential to save lives, and the international intellectual property system should be leveraged to drive innovation and bring those therapies to people who need them, said the leaders of global health, trade and intellectual property agencies at a Trilateral Symposium on […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Civil Society Pressures French Leaders To Adopt Transparency Amendments 06/11/2019 Grace Ren A coalition of over 40 personalities – from doctors and economists to actors and health access activists – released an open letter Tuesday calling on the French Prime Minister Edouard Philippe and the Minister of Health Agnès Buzyn to support a series of amendments to the French Social Security Budget Bill for 2020 providing for […] Continue reading -> Challenges & Opportunities Of Cutting-Edge Health Technologies Discussed At WTO-WHO-WIPO Symposium 31/10/2019 Grace Ren Cutting-edge health technologies – such as gene editing therapies for cancer – have the potential to save lives, and the international intellectual property system should be leveraged to drive innovation and bring those therapies to people who need them, said the leaders of global health, trade and intellectual property agencies at a Trilateral Symposium on […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Challenges & Opportunities Of Cutting-Edge Health Technologies Discussed At WTO-WHO-WIPO Symposium 31/10/2019 Grace Ren Cutting-edge health technologies – such as gene editing therapies for cancer – have the potential to save lives, and the international intellectual property system should be leveraged to drive innovation and bring those therapies to people who need them, said the leaders of global health, trade and intellectual property agencies at a Trilateral Symposium on […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Posts navigation Older postsNewer posts